- Stocks
- Healthcare
- NASDAQ: ALKS

Price (delayed)

$28.02

Market cap

$4.61B

P/E Ratio

16.2

Dividend/share

N/A

EPS

$1.73

Enterprise value

$4.45B

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by

The debt has contracted by 6% YoY

ALKS's quick ratio is up by 4.3% since the previous quarter

The EPS has soared by 184% year-on-year but it has declined by 34% since the previous quarter

Alkermes's net income has soared by 180% YoY but it has decreased by 34% from the previous quarter

Alkermes's gross profit has decreased by 15% from the previous quarter

ALKS's P/E is 4.2% above its last 4 quarters average of 14.7

What are the main financial stats of ALKS

Market
Valuations
Earnings

Shares outstanding

164.67M

Market cap

$4.61B

Enterprise value

$4.45B

Price to book (P/B)

3.69

Price to sales (P/S)

3.13

EV/EBIT

17.9

EV/EBITDA

14.81

EV/Sales

2.95

Revenue

$1.51B

EBIT

$248.42M

EBITDA

$300.34M

Free cash flow

$425.87M

Per share
Balance sheet
Liquidity

EPS

$1.73

Free cash flow per share

$2.53

Book value per share

$7.59

Revenue per share

$8.96

TBVPS

$12.61

Total assets

$2.21B

Total liabilities

$922.84M

Debt

$368M

Equity

$1.28B

Working capital

$1.03B

Debt to equity

0.29

Current ratio

2.99

Quick ratio

2.41

Net debt/EBITDA

-0.56

Margins
Efficiency
Dividend

EBITDA margin

19.9%

Gross margin

83.3%

Net margin

19.1%

Operating margin

24.9%

Return on assets

13.2%

Return on equity

22.7%

Return on invested capital

17.1%

Return on capital employed

14.7%

Return on sales

16.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Alkermes stock price performed over time

Intraday

5.7%

1 week

13.67%

1 month

15.88%

1 year

-9.14%

YTD

1.01%

QTD

16.27%

How have Alkermes's revenue and profit performed over time

Revenue

$1.51B

Gross profit

$1.26B

Operating income

$375.62M

Net income

$288.72M

Gross margin

83.3%

Net margin

19.1%

Alkermes's net income has soared by 180% YoY but it has decreased by 34% from the previous quarter

The net margin has soared by 173% YoY but it has contracted by 24% from the previous quarter

Alkermes's operating income has decreased by 31% from the previous quarter but it has increased by 15% YoY

The company's operating margin fell by 21% QoQ but it rose by 12% YoY

What is Alkermes's growth rate over time

What is Alkermes stock price valuation

P/E

16.2

P/B

3.69

P/S

3.13

EV/EBIT

17.9

EV/EBITDA

14.81

EV/Sales

2.95

The EPS has soared by 184% year-on-year but it has declined by 34% since the previous quarter

ALKS's P/E is 4.2% above its last 4 quarters average of 14.7

The company's equity rose by 2.3% QoQ

The revenue has contracted by 13% from the previous quarter but it has grown by 3.1% YoY

ALKS's P/S is 8% below its 5-year quarterly average of 3.2 but 6% above its last 4 quarters average of 2.8

How efficient is Alkermes business performance

The ROA has soared by 159% YoY but it fell by 34% QoQ

The return on equity has surged by 141% year-on-year but it has declined by 33% since the previous quarter

The ROS has soared by 72% year-on-year but it has declined by 24% since the previous quarter

The ROIC has soared by 71% YoY but it has decreased by 35% from the previous quarter

What is ALKS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ALKS.

How did Alkermes financials performed over time

Alkermes's total assets is 139% higher than its total liabilities

The current ratio has contracted by 7% from the previous quarter but it has grown by 4.2% YoY

The company's total liabilities rose by 6% QoQ

The debt is 71% less than the equity

The debt has contracted by 6% YoY

The debt to equity is down by 3.3% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.